Cargando…
Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
OBJECTIVE: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients. METHODS: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246770/ https://www.ncbi.nlm.nih.gov/pubmed/37293505 http://dx.doi.org/10.3389/fendo.2023.1176256 |
_version_ | 1785055098169196544 |
---|---|
author | Peng, Xiaojuan Chen, Sisi Zhong, Lu Li, Yuting Wu, Chutian Zhong, Lixian Chen, Weiwei Yang, Jinying Zeng, Jiahua Tang, Shaohui |
author_facet | Peng, Xiaojuan Chen, Sisi Zhong, Lu Li, Yuting Wu, Chutian Zhong, Lixian Chen, Weiwei Yang, Jinying Zeng, Jiahua Tang, Shaohui |
author_sort | Peng, Xiaojuan |
collection | PubMed |
description | OBJECTIVE: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients. METHODS: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM patients were randomly assigned to the CP group or the Glipizide group (G group) in a 2:1 ratio. T2DM-associated metabolic phenotypes, gut microbiota and metabolites including short-chain fatty acids (SCFAs) and bile acids (BAs) were detected. RESULTS: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters (fasting plasma glucose (FBG), 2-hour post-meal blood glucose (2hPBG), the area under curve of oral glucose tolerance test glucose (OGTT glucose AUC)). Moreover, CP also resulted in the significant improvement in the levels of blood lipid and blood pressure. Notably, the improvement in blood lipid(triglycerides (TG) and high-density lipoprotein cholesterol (HDL-c)) and blood pressure (diastolic blood pressure (DBP)) was significantly greater in the CP group compared with the G group. Furthermore, the liver and kidney function parameters did not significantly change in both CP group and the G group over the 84-day period. Additionally, the enrichment of potentially beneficial bacteria (Faecalibacterium and Akkermansia), SCFAs and unconjugated BAs and the depletion of potential pathogenic bacteria (Prevotella_9) and conjugated BAs were observed in the CP group, while the abundances of the gut microbial were kept stable in the G group after intervention. CONCLUSION: CP displays a more beneficial effect in the alleviation of T2DM-associated metabolic phenotypes than glipizide by regulating gut microbiota and metabolites in T2DM patients, with no significant effects on liver and kidney function. |
format | Online Article Text |
id | pubmed-10246770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102467702023-06-08 Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial Peng, Xiaojuan Chen, Sisi Zhong, Lu Li, Yuting Wu, Chutian Zhong, Lixian Chen, Weiwei Yang, Jinying Zeng, Jiahua Tang, Shaohui Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients. METHODS: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM patients were randomly assigned to the CP group or the Glipizide group (G group) in a 2:1 ratio. T2DM-associated metabolic phenotypes, gut microbiota and metabolites including short-chain fatty acids (SCFAs) and bile acids (BAs) were detected. RESULTS: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters (fasting plasma glucose (FBG), 2-hour post-meal blood glucose (2hPBG), the area under curve of oral glucose tolerance test glucose (OGTT glucose AUC)). Moreover, CP also resulted in the significant improvement in the levels of blood lipid and blood pressure. Notably, the improvement in blood lipid(triglycerides (TG) and high-density lipoprotein cholesterol (HDL-c)) and blood pressure (diastolic blood pressure (DBP)) was significantly greater in the CP group compared with the G group. Furthermore, the liver and kidney function parameters did not significantly change in both CP group and the G group over the 84-day period. Additionally, the enrichment of potentially beneficial bacteria (Faecalibacterium and Akkermansia), SCFAs and unconjugated BAs and the depletion of potential pathogenic bacteria (Prevotella_9) and conjugated BAs were observed in the CP group, while the abundances of the gut microbial were kept stable in the G group after intervention. CONCLUSION: CP displays a more beneficial effect in the alleviation of T2DM-associated metabolic phenotypes than glipizide by regulating gut microbiota and metabolites in T2DM patients, with no significant effects on liver and kidney function. Frontiers Media S.A. 2023-05-24 /pmc/articles/PMC10246770/ /pubmed/37293505 http://dx.doi.org/10.3389/fendo.2023.1176256 Text en Copyright © 2023 Peng, Chen, Zhong, Li, Wu, Zhong, Chen, Yang, Zeng and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Peng, Xiaojuan Chen, Sisi Zhong, Lu Li, Yuting Wu, Chutian Zhong, Lixian Chen, Weiwei Yang, Jinying Zeng, Jiahua Tang, Shaohui Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
title | Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
title_full | Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
title_fullStr | Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
title_full_unstemmed | Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
title_short | Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
title_sort | cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in chinese t2dm patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246770/ https://www.ncbi.nlm.nih.gov/pubmed/37293505 http://dx.doi.org/10.3389/fendo.2023.1176256 |
work_keys_str_mv | AT pengxiaojuan cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT chensisi cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT zhonglu cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT liyuting cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT wuchutian cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT zhonglixian cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT chenweiwei cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT yangjinying cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT zengjiahua cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial AT tangshaohui cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial |